Scarica l'app Stockscreener
35.63
0.45%
0.16
Dopo l'orario di chiusura:
35.39
-0.24
-0.67%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics rises after Q4 updates on obesity therapy - MSN
Why Viking Therapeutics (VKTX) Is Up 12.6% After Fast-Tracking VK2735 Into Late-Stage Obesity TrialsAnd What's Next - simplywall.st
Why Is Viking Therapeutics (VKTX) Up 16.3% Since Last Earnings Report? - Yahoo Finance
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
Viking Therapeutics Phase 3 Obesity Move Tests VK2735 Valuation Gap - Sahm
Is Viking Therapeutics (VKTX) Price Move Justified By DCF And Book Value Signals - Yahoo Finance
Why Has Viking Therapeutics (VKTX) Increased by 16.3% Since Its Previous Earnings Announcement? - Bitget
Jefferies Maintains Buy on Viking Therapeutics, Inc. (VKTX) March 2026 - Meyka
Jefferies reiterates Buy on Viking Therapeutic stock, $101 target - Investing.com
Can Viking Therapeutics Capitalize on Weight Loss Drugs for a Comeback? - NAI500
Net current asset value per share of Viking Therapeutics, Inc. – LS:A12GD6 - TradingView
WINTON GROUP Ltd Buys Shares of 68,700 Viking Therapeutics, Inc. $VKTX - MarketBeat
Here's Why Viking Therapeutics Stock Recovered and Can Soar in 2026 - The Motley Fool
Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026 - AOL.com
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know - MSN
How Viking Therapeutics Inc. (VKTX) Affects Rotational Strategy Timing - Stock Traders Daily
Insider Buying: Neil Aubuchon Acquires Shares of Viking Therapeu - GuruFocus
Management Purchase Signals Confidence in Viking Therapeutics' Pipeline - AD HOC NEWS
Viking Therapeutics (NASDAQ:VKTX) Insider Acquires $149,912.50 in Stock - MarketBeat
Viking Therapeutics (VKTX) CCO buys 4,475 shares at $33.50 - Stock Titan
Viking Therapeutics Stock Gets RS Rating Upgrade - Investor's Business Daily
Viking Therapeutics at Leerink Conference: Strategic Moves in Obesity Market - Investing.com
2 Under-the-Radar Stocks to Buy and Hold - AOL.com
VKTX: Rapid progress in dual agonist obesity trials sets up major data and commercial milestones for 2026 - TradingView
VKTX: Phase 3 obesity trials advance rapidly, with pivotal data and new oral options expected in 2026 - TradingView
Viking Therapeutics (VKTX) Breaks Out From Multi-Year Down Trend - Bitget
Is Viking Therapeutics (VKTX) One of the Shorted Biotech Stocks to Invest in - Yahoo Finance
Top 10 Takeover Targets of 2026 - Genetic Engineering and Biotechnology News
Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street - AOL.com
Viking Therapeutics, Inc. $VKTX Shares Purchased by Rhenman & Partners Asset Management AB - MarketBeat
Viking Therapeutics (VKTX) Valuation Check After Recent Share Price Swings And Analyst Fair Value Gap - Yahoo Finance
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is It Time To Reassess Viking Therapeutics (VKTX) After Its Recent Share Price Swings - simplywall.st
Raymond James lowers Viking Therapeutics, Inc. (VKTX) price target amid optimistic clinical initiative outlook - MSN
Assessing Viking Therapeutics (VKTX) Valuation After Sharp Swings And Obesity Drug Optimism - simplywall.st
Viking Therapeutics, Inc. (VKTX) Experiences a Steeper Decline Compared to the Overall Market: Important Takeaways - Bitget
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights - finance.yahoo.com
Notable Two Hundred Day Moving Average CrossVKTX - Nasdaq
Viking Therapeutics to Participate at Upcoming Investor Conferences - PR Newswire
Viking Therapeutics Stock Soars To 10-Month High After Canaccord Boost – Retail Traders See It As Next Big Obesity Play - Stocktwits
Biotech Viking Therapeutics heads to twin Miami investor conferences - Stock Titan
Raymond James Lowers Viking Therapeutics, Inc. (VKTX) Price Target Amid Optimistic Clinical Initiative Outlook - Finviz
VKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring A 178% Upside Potential - DirectorsTalk Interviews
Viking Therapeutics (VKTX) Stock: Financial Performance Highlights 22% Revenue Growth and 44% Profit Increase in 2025 - MEXC
Viking Therapeutics, Inc. (VKTX) Stock: Revenue Surges 22% as Adjusted Net Income Jumps 44% in 2025 - MEXC
Rafferty Asset Management LLC Purchases 41,888 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Vanguard Group Reduces Stake in Viking Therapeutics - National Today
Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal
Viking Therapeutics, Inc. $VKTX Shares Sold by Vanguard Group Inc. - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Upgraded at BTIG Research - MarketBeat
Viking Therapeutics (VKTX) Is Up 9.1% After Advancing VK2735 As Rival Obesity Drug Stumbles - simplywall.st
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today - Yahoo Finance
Viking Therapeutics: The High-Stakes Weight Loss Contender - MarketBeat
Viking Therapeutics Advances VK2735 As Obesity Data And Valuation Draw Focus - simplywall.st
Viking Therapeutics Gains Ground Amid Novo Nordisk's Clinical Setback - AD HOC NEWS
Is Viking Therapeutics (VKTX) Still Attractive After Its Recent Share Price Surge - Yahoo Finance
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. - The Motley Fool
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):